Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ALXN1720 in adults with generalized myasthenia gravis
CTR20232711Phase 3Active
- Sponsor
- 不适用/ 阿斯利康全球研发（中国）有限公司
- Start
- Nov 2023
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of gefurulimab in myasthenia gravis (MG), sponsored by 不适用/ 阿斯利康全球研发（中国）有限公司. Started Nov 2023; status: active.
02
Drugs
gefurulimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20232711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232711.